SLDB Profile
Solid Biosciences Inc. (SLDB) is a life sciences company that develops therapies for Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle degeneration and weakness. The company's lead product candidate, SGT-001, is a gene therapy designed to deliver a functional copy of the dystrophin gene to muscle cells, thereby addressing the underlying cause of DMD. SGT-001 is currently being evaluated in a Phase 1/2 clinical trial for the treatment of DMD. Solid Biosciences is also developing other product candidates for the treatment of DMD, including a follow-on gene therapy program, a gene editing program, and a small molecule program. The company is headquartered in Cambridge, Massachusetts, and as of September 2021, had a market capitalization of approximately $160 million.
|
